[go: up one dir, main page]

MX2018014178A - Anticuerpo anti-fgfr2. - Google Patents

Anticuerpo anti-fgfr2.

Info

Publication number
MX2018014178A
MX2018014178A MX2018014178A MX2018014178A MX2018014178A MX 2018014178 A MX2018014178 A MX 2018014178A MX 2018014178 A MX2018014178 A MX 2018014178A MX 2018014178 A MX2018014178 A MX 2018014178A MX 2018014178 A MX2018014178 A MX 2018014178A
Authority
MX
Mexico
Prior art keywords
fgfr2 antibody
antibody
fgfr2
binds
provides
Prior art date
Application number
MX2018014178A
Other languages
English (en)
Inventor
Jun Hasegawa
Tatsuji Matsuoka
Atsushi Urano
Toshiaki Ohtsuka
Chigusa Yoshimura
Toshinori Agatsuma
Takako Kimura
Yumi Matsui
Yasuki Kamai
Reimi Kawaida
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2018014178A publication Critical patent/MX2018014178A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G01N33/5753—
    • G01N33/57535—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)

Abstract

La presente invención proporciona un anticuerpo que se une a un receptor del factor de crecimiento de fibroblastos.
MX2018014178A 2012-04-09 2014-10-09 Anticuerpo anti-fgfr2. MX2018014178A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012088299 2012-04-09

Publications (1)

Publication Number Publication Date
MX2018014178A true MX2018014178A (es) 2021-11-16

Family

ID=49327760

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012230A MX360851B (es) 2012-04-09 2013-04-09 Anticuerpo anti-fgfr2.
MX2018014178A MX2018014178A (es) 2012-04-09 2014-10-09 Anticuerpo anti-fgfr2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014012230A MX360851B (es) 2012-04-09 2013-04-09 Anticuerpo anti-fgfr2.

Country Status (19)

Country Link
US (2) US9714298B2 (es)
EP (1) EP2837685B1 (es)
JP (1) JP6188681B2 (es)
KR (1) KR102115143B1 (es)
CN (1) CN104334724B (es)
AU (1) AU2013247645B2 (es)
BR (2) BR122016008098A2 (es)
CA (1) CA2870126C (es)
CO (1) CO7111294A2 (es)
ES (1) ES2831309T3 (es)
IL (1) IL235004A0 (es)
MX (2) MX360851B (es)
NZ (1) NZ631445A (es)
PH (1) PH12014502269A1 (es)
RU (1) RU2014145001A (es)
SG (2) SG11201406422TA (es)
TW (1) TWI669313B (es)
WO (1) WO2013154206A1 (es)
ZA (1) ZA201407316B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210949A1 (es) 2013-08-01 2021-05-24 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
CN105792844B (zh) * 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
UA123763C2 (uk) * 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
US10633415B2 (en) * 2015-03-06 2020-04-28 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
JP6887944B2 (ja) * 2015-04-08 2021-06-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
US10881734B2 (en) 2015-04-20 2021-01-05 Daiichi Sankyo Company, Limited Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
SG11201802352VA (en) 2015-09-24 2018-04-27 Daiichi Sankyo Co Ltd Anti-garp antibody
TWI791422B (zh) * 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
ES3041987T3 (en) 2017-05-16 2025-11-17 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
WO2019059302A1 (ja) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
KR20210143237A (ko) 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
TW202102225A (zh) 2019-03-25 2021-01-16 日商第一三共股份有限公司 抗her2抗體-吡咯并苯二氮呯衍生物結合物
TWI841715B (zh) 2019-03-27 2024-05-11 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
WO2021006212A1 (ja) * 2019-07-08 2021-01-14 テルモ株式会社 ハイブリドーマおよびその製造方法、並びにモノクローナル抗体およびその製造方法
EP4273166A4 (en) * 2020-12-29 2025-04-16 Shenzhen Forward Pharmaceuticals Co., Limited ANTI-FGFR2 ANTIBODIES AND USE THEREOF
WO2025130860A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体及其应用
US20250222125A1 (en) * 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2012021841A2 (en) * 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
ES2646168T3 (es) 2008-11-07 2017-12-12 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
BRPI1006448B1 (pt) * 2009-03-25 2021-08-17 Genentech, Inc Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, micro­organismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
SG185487A1 (en) * 2010-05-11 2012-12-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
US9498532B2 (en) * 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates

Also Published As

Publication number Publication date
WO2013154206A1 (ja) 2013-10-17
MX360851B (es) 2018-11-16
MX2014012230A (es) 2015-07-23
IL235004A0 (en) 2014-12-31
ES2831309T3 (es) 2021-06-08
BR122016008098A2 (pt) 2019-08-27
US20150125454A1 (en) 2015-05-07
AU2013247645B2 (en) 2019-02-14
EP2837685A1 (en) 2015-02-18
JP6188681B2 (ja) 2017-08-30
JPWO2013154206A1 (ja) 2015-12-21
US9481733B2 (en) 2016-11-01
PH12014502269A1 (en) 2014-12-10
CO7111294A2 (es) 2014-11-10
US9714298B2 (en) 2017-07-25
TWI669313B (zh) 2019-08-21
CA2870126C (en) 2020-10-27
RU2014145001A (ru) 2016-06-10
WO2013154206A9 (ja) 2014-06-05
ZA201407316B (en) 2015-12-23
SG11201406422TA (en) 2014-11-27
CA2870126A1 (en) 2013-10-17
US20160009820A1 (en) 2016-01-14
HK1205180A1 (en) 2016-01-22
EP2837685B1 (en) 2020-09-09
SG10201608382QA (en) 2016-12-29
EP2837685A4 (en) 2016-02-24
CN104334724B (zh) 2020-09-01
AU2013247645A1 (en) 2014-10-30
KR102115143B1 (ko) 2020-05-28
KR20150002646A (ko) 2015-01-07
CN104334724A (zh) 2015-02-04
BR112014025037A2 (pt) 2018-07-31
NZ631445A (en) 2017-02-24
TW201345924A (zh) 2013-11-16

Similar Documents

Publication Publication Date Title
MX2018014178A (es) Anticuerpo anti-fgfr2.
CY1120916T1 (el) Συζευγματα πυρρολοβενζοδιαζεπινης-αντισωματος εναντι του psma
MX2015004449A (es) Conjugados del anticuerpo pirrolobenzodiazepina.
CY1120327T1 (el) Συζευγματα αντισωματος-πυρρολοβενζοδιαζεπινης
CY1119782T1 (el) Συζευγματα πυρρολοβενζοδιαζεπινης-αντισωματος αντι-cd22
MX2015004423A (es) Conjugados del anticuerpo pirrolobenzodiazepina - anti-her2.
BR112016019866A2 (pt) terapias de combinação com anticorpos anti-cd38
BR112016000903A2 (pt) anticorpos
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
CR20140440A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
CO7151521A2 (es) Anticuerpos anti-fcrn
CO7020893A2 (es) Conjunto de desgaste
TR201905829T4 (tr) Buzdolabı.
SG10201811017QA (en) Novel antibody frameworks
UY34644A (es) Polipéptidos de unión a cx3cr1
UY34547A (es) Un Escenario de Elevación Compuesto
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
UY34582A (es) Anticuerpos anti-cxcr3
EA201491959A1 (ru) Агонистические пептиды для par4
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX350335B (es) Anticuerpos que enlazan alfa-v beta-8 integrina.
EP2832857A4 (en) ANTI-SIGLEC15 ANTIBODIES WITH MODIFIED CDR
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
CO7111295A2 (es) Anticuerpo anti-rob04
UY34408A (es) Nuevos moduladores de trpv3